Developmental toxicity of the class III antiarrhythmic agent almokalant in mice. Adverse effects mediated via induction of embryonic heart rhythm abnormalities

Arzneimittel-Forschung/Drug Research

Volumn 50, Issue 6, 2000, Pages 520-525

  Sköld, Anna Carin ^a,b   Danielsson, Bengt R ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Almokalant, developmental toxicity, embryonic heart rhythm abnormalities, mouse; CAS 123955 10 2; Class III antiarrhythmics

Indexed keywords

ALMOKALANT; ANTIARRHYTHMIC AGENT;

ANIMAL MODEL; ARTICLE; BONE DEFECT; BRADYCARDIA; CONTROLLED STUDY; EMBRYO; EMBRYO DEATH; EMBRYOTOXICITY; FETUS HEART RATE; FETUS WEIGHT; HEART ARREST; HEART ARRHYTHMIA; MOUSE; NONHUMAN;

EID: 0033930098     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300241     Document Type: Article

References (25)

1. + current by almokalant in rabbit ventricular myocytes, Circ. Res. 73, 857 (1993)
2. [2] Danielsson, B. R., in: Developmental Toxicology Pre-clinical and Clinical Data in Retrospect, A. Sundwall, B. R. Danielsson, O. Hagberg et al. (eds.), pp. 45-52, Tryckgruppen, Stockholm (1993)
3. [3] Abrahamsson, C., Palmer, M., Ljung, B. et al., Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant, Cardiovasc. Res. 28, 337 (1994)
4. [4] Webster, W. S., Brown-Woodman, P. D., Snow, M. D. et al., Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity, Teratology 53, 168 (1996)
5. [5] Spence, S. G., Vetter, C., Hoe, C. M., Effects of the class III antiarrhythmic, dofetilide (UK-68,798) on the heart rate of midgestation rat embryos, in vitro, Teratology 49, 282 (1994)
6. [6] Marks, T. A., Terry, R. D., Developmental toxicity of ibutilide fumarate in rats after oral administration, Teratology 54, 157 (1996)
7. [7] Ban, Y., Konishi, R., Kawana, K. et al., Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats, Arch. Toxicol. 69, 65 (1994)
8. [8] Barrow, M. V., Taylor, W. J., A rapid method for detecting malformations in rat fetuses, J. Morphol. 127, 291 (1969)
9. [9] New, D. A., Whole-embryo culture and the study of mammalian embryos during organogenesis, Biol. Rev. Cambridge Philos. Soc. 53, 81 (1978)
10. [10] Statistical methods, p. 59, The Iowa State University Press, Ames, Iowa (1967)
11. [11] Kendall, M., Stuart, A., The advanced theory of statistics, p. 580, Macmillan Publishing, New York (1979)
12. [12] Winer, B. J., Brown, D. R., Michels, K. M., Statistical principles in Experimental Design, p. 3., McGraw Hill, New York (1991)
13. [13] Davies, M. P., An, R. H., Doevendans, P. et al., Developmental changes in ionic channel activity in the embryonic murine heart, Circ. Res. 78, 15 (1996)
14. + channels in mouse heart, Circ. Res. 79, 79 (1996)
15. [15] Grabowski, C. T., in: Advances in Teratology, D. H. M. Woollam (ed.), pp. 125-169, Logos Press, London (1970)
16. [16] Wellfelt, K., Sköld, A. C., Wallin, A. et al., Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species, Reprod.-Toxicol. 13, 93 (1999)
17. + channels by phenytoin in rat neuroblastoma cells, Br. J. Pharmacol. 120, 647 (1997)
18. [18] Finnell, R. H., Dansky, L. V., Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 1: Animal studies, Reprod.Toxicol. 5, 281 (1991)
19. [19] Hanson, J. W., Teratogen update: fetal hydantoin effects, Teratology 33, 349 (1986)
20. [20] Gaily, E., Distal phalangeal hypoplasia in children with prenatal phenytoin exposure: results of a controlled anthropometric study, Am. J. Med. Genet. 35, 574 (1990)
21. [21] Danielsson, B. R., Danielson, K., Tomson, T. Phenytoin causes phalangeal hypoplasia in the rabbit fetus at clinically relevant free plasma concentrations, Teratology 52, 252 (1995)
22. [22] Danielsson, B. R., Azarbayjani, F., Sköld, A. C. et al., Initiation of phenytoin teratogenesis: pharmacologically induced embryonic bradycardia and arrhythmia resulting in hypoxia and possible free radical damage at reoxygenation, Teratology 56, 271 (1997)
23. [23] Hetzel, S., Brown, K. S., Facial clefts and lip hematomas in mouse fetuses given diphenyhydantoin, J. Dent. Res. 54A, 83 (1975)
24. [24] Danielson, M. K., Danielsson, B. R., Marchner, H. et al., Histopathological and hemodynamic studies supporting hypoxia and vascular disruption as explanation to phenytoin teratogenicity, Teratology 46, 485 (1992)
25. [25] Leist, K. H., Grauwiler, J., Fetal pathology in rats following uterine-vessel clamping on day 14 of gestation, Teratology 10, 55 (1974)